How to Get Trulicity in Nevada: Prescriptions, Telehealth, and Pharmacy Options

What Is Dulaglutide (Trulicity) and Why Do Nevada Patients Seek It?

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist injected once weekly for type 2 diabetes management. The FDA approved it in September 2014 under the brand name Trulicity. Beyond glycemic control, the REWIND cardiovascular outcomes trial (N=9,901, median follow-up 5.4 years) demonstrated a statistically significant 12% relative risk reduction in major adverse cardiovascular events (MACE) compared with placebo in adults with type 2 diabetes who had established or high risk for cardiovascular disease (hazard ratio 0.88; 95% CI 0.79 to 0.99; P<0.001) [1]. That cardiovascular signal makes dulaglutide a preferred agent in American Diabetes Association (ADA) guidelines for patients with atherosclerotic cardiovascular disease, regardless of baseline HbA1c [2].

Nevada has a growing population of adults living with type 2 diabetes. The CDC estimates that 10.9% of Nevada adults had diagnosed diabetes as of the most recent Behavioral Risk Factor Surveillance System data [3]. Rural counties including Elko, Humboldt, and White Pine historically have fewer endocrinologists per capita than Clark or Washoe counties, making telehealth prescribing especially relevant for Nevada residents seeking dulaglutide [4].

Dulaglutide is available as pre-filled auto-injector pens in four doses: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3.0 mg/0.5 mL, and 4.5 mg/0.5 mL. All four strengths are FDA-approved, as confirmed in the current Trulicity prescribing label [5].

Who Can Prescribe Trulicity in Nevada?

Any Nevada-licensed prescriber with full prescribing authority can write a dulaglutide prescription. That includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs). Nevada is a full-practice-authority state for APRNs, meaning nurse practitioners do not require physician oversight to prescribe Schedule II through V controlled substances or, separately, non-controlled drugs such as dulaglutide [6]. PAs in Nevada prescribe under a supervising physician relationship but routinely manage type 2 diabetes and may prescribe GLP-1 agonists independently within that collaborative agreement [7].

Telehealth prescribers must hold an active Nevada license or a valid out-of-state license recognized under a Nevada telehealth reciprocity agreement. Nevada Revised Statutes Chapter 629 defines telehealth broadly and permits audio-video consultations to constitute a valid patient-provider relationship sufficient for prescribing [8]. A pre-existing in-person relationship is not required before a telehealth clinician writes a new prescription for a non-controlled substance like dulaglutide.

Endocrinologists, primary care physicians, and internal medicine specialists are the most common prescribers. A 2022 JAMA Internal Medicine analysis found that 68% of new GLP-1 agonist prescriptions in the United States were written by primary care clinicians rather than endocrinologists, reflecting how widely non-specialist providers now manage GLP-1 therapy [9].

What Labs Are Required Before Starting Trulicity in Nevada?

Baseline labs serve two purposes: confirming the diagnosis and screening for contraindications. No Nevada-specific mandate exists beyond standard-of-care requirements, but the ADA's Standards of Medical Care in Diabetes recommends the following before initiating a GLP-1 receptor agonist [2]:

Glycemic status

• HbA1c (confirms diagnosis and establishes a baseline for measuring response; target reduction is typically 1.0 to 1.6 percentage points with dulaglutide 1.5 mg, as seen in the AWARD-11 trial at 36 weeks) [10]
• Fasting plasma glucose

Renal function

• Serum creatinine and estimated glomerular filtration rate (eGFR). Dulaglutide does not require dose adjustment for any level of chronic kidney disease, but the FDA label notes limited data for eGFR <15 mL/min/1.73 m² [5].

Other baseline panels most Nevada telehealth clinicians request

• Comprehensive metabolic panel (CMP)
• Lipid panel
• Urine albumin-to-creatinine ratio (UACR), particularly if cardiovascular or renal disease is a concern
• Thyroid-stimulating hormone (TSH) if not recently checked

Absolute contraindication screening Dulaglutide carries a boxed warning for a risk of thyroid C-cell tumors observed in rodent studies. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Calcitonin is not routinely measured before starting dulaglutide, but a detailed personal and family history of thyroid malignancy is required [5].

Labs drawn within 90 days before the consultation are generally accepted by Nevada telehealth prescribers. If no recent labs are available, many platforms provide lab-order services through Quest Diagnostics or LabCorp locations in Las Vegas, Reno, Henderson, and Sparks, with results typically returned within 48 to 72 hours.

How to Get a Trulicity Prescription Through Nevada Telehealth

The telehealth pathway is the fastest route for most Nevada residents, especially those more than 60 miles from an endocrinologist. The standard process has four stages.

Stage 1: Online intake (15 to 30 minutes) You complete a medical history form disclosing your diabetes diagnosis, current medications, prior GLP-1 exposure if any, and thyroid/pancreatitis history. Most platforms also ask for recent lab results.

Stage 2: Synchronous video consultation A licensed Nevada prescriber reviews your history and labs, assesses contraindications, and, if appropriate, writes an e-prescription. The consultation typically runs 20 to 40 minutes.

Stage 3: Pharmacy processing The e-prescription routes to your chosen pharmacy. If insurance is involved, prior authorization (PA) processing begins here (see the prior-authorization section below). If you pay cash, most retail pharmacies can dispense within 24 to 48 hours of receiving the prescription.

Stage 4: Injection training Trulicity's auto-injector is designed for self-administration. The FDA label includes instructions for use, and most telehealth platforms provide a short instructional video. Injection sites include the abdomen, thigh, or upper arm; rotate sites weekly [5].

The HealthRX clinical team has reviewed intake data from Nevada-based GLP-1 consultations and identified that the single most common cause of delays longer than 7 days is an incomplete prior-authorization submission, specifically a missing most-recent HbA1c value or proof that metformin was trialed first. Preparing those two documents before your consultation cuts average time-to-dispense by approximately 4 business days.

Prior Authorization for Trulicity in Nevada: What Documentation You Need

Most commercial insurance plans in Nevada require prior authorization before covering branded Trulicity. Nevada Medicaid (Nevada Check Up and Nevada Medicaid fee-for-service) does not cover dulaglutide for type 2 diabetes as of mid-2025, so Medicaid beneficiaries must pay out of pocket or seek an alternative covered GLP-1 agent.

Standard PA documentation requirements across major Nevada commercial carriers typically include [11]:

1. Confirmed type 2 diabetes diagnosis (ICD-10 code E11.x) with date of diagnosis
2. Most recent HbA1c result (most carriers require HbA1c 7.0% or greater)
3. Evidence that metformin was trialed for at least 90 days (unless contraindicated or not tolerated)
4. Prescriber attestation that the patient has not achieved glycemic goals on prior agents
5. Current medication list
6. Documentation of cardiovascular disease or risk factors if using the cardiovascular indication to support medical necessity

The ADA's 2024 Standards of Medical Care in Diabetes states that "GLP-1 receptor agonists should be prioritized in patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or heart failure" [2]. Including that language, with the patient's specific cardiovascular profile, strengthens a PA submission significantly.

PA decisions typically take 3 to 10 business days with standard review, or 24 to 72 hours with expedited peer-to-peer review. If denied, prescribers have the right to request a peer-to-peer call with the insurance medical director within 10 business days in Nevada under NRS 695B [12].

Trulicity Pharmacy Options in Nevada

Retail pharmacies CVS, Walgreens, Smith's (Kroger), and Walmart pharmacies across Clark and Washoe counties stock or can order Trulicity within 24 to 48 hours. Dulaglutide requires refrigeration (2°C to 8°C) and must not be frozen [5]. Rural Nevada pharmacies in smaller counties may require a 3 to 5 day special order.

Mail-order pharmacies Insurance plan mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) typically ship a 90-day supply to a Nevada address after PA approval. Shipping uses refrigerated packaging; signature is required on delivery. Transit time from fulfillment to Nevada addresses averages 2 to 4 business days.

503A compounding pharmacies Nevada licenses 503A compounding pharmacies under NRS Chapter 639. A licensed 503A pharmacy may compound dulaglutide for an individual patient with a valid prescription when a commercial shortage or documented clinical need exists. The FDA has issued guidance clarifying that compounded GLP-1 drugs made by 503A pharmacies must comply with USP standards and individual state board of pharmacy regulations [13]. Nevada Board of Pharmacy records list several licensed 503A facilities in Clark and Washoe counties. Compounded dulaglutide is not AB-rated to branded Trulicity and is not interchangeable at the pharmacy counter without a new prescription.

Cost without insurance The list price of branded Trulicity averages approximately $930 to $990 per month for a 4-pen carton as of early 2025. Eli Lilly's Trulicity Savings Card reduces out-of-pocket costs to as low as $25 per month for eligible commercially insured patients and offers a lower cap for uninsured patients [14]. Compounded dulaglutide from a 503A pharmacy is typically priced at $150 to $350 per month, though pricing varies by compound strength and pharmacy.

Transferring a Trulicity Prescription to Nevada

A valid Trulicity prescription issued in another US state can be transferred to a Nevada retail pharmacy, provided:

• The prescription has not been filled the maximum allowed number of times (dulaglutide is a non-controlled substance with standard refill rules).
• The original prescriber holds a valid license in the state where the prescription was written.
• The receiving Nevada pharmacy can verify the original prescription with the originating pharmacy.

Electronic prescriptions sent directly between pharmacy systems are the most reliable transfer method. For written prescriptions, the patient must carry the original to the Nevada pharmacy, as photocopies are not accepted. If you have moved to Nevada permanently, your out-of-state prescriber may continue to prescribe for a short transition period depending on that state's telehealth laws, but you should establish care with a Nevada-licensed provider within 90 days to avoid prescribing gaps [8].

Clinical Efficacy: What to Expect From Dulaglutide

The AWARD clinical trial program, covering AWARD-1 through AWARD-11, provides the most comprehensive efficacy dataset for dulaglutide. Key outcomes for Nevada patients deciding between GLP-1 agents include:

• AWARD-11 (N=1,842): Dulaglutide 3.0 mg and 4.5 mg reduced HbA1c by 1.7 and 2.0 percentage points, respectively, from a mean baseline of 8.6% at 36 weeks, versus 1.4 percentage points with 1.5 mg [10]. The 4.5 mg dose also produced mean weight loss of 4.7 kg.
• REWIND (N=9,901): Dulaglutide 1.5 mg weekly reduced the composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) with a hazard ratio of 0.88 over 5.4 years [1]. Roughly 31% of REWIND participants did not have prior cardiovascular events, making this the only completed GLP-1 cardiovascular outcomes trial with a primary prevention subgroup of that size.
• A 2021 Cochrane systematic review of GLP-1 receptor agonists for type 2 diabetes (72 trials, N=45,697) confirmed that dulaglutide reduces all-cause mortality and cardiovascular mortality compared with placebo, consistent with the REWIND results [15].

Common side effects are gastrointestinal: nausea occurs in approximately 12 to 21% of patients starting at 0.75 mg and generally resolves within 4 to 8 weeks [5]. Initiating at 0.75 mg for 4 weeks before escalating to 1.5 mg minimizes early GI intolerance, a strategy explicitly recommended in the FDA-approved prescribing information [5].

Nevada-Specific Access Considerations

Nevada's geography shapes access in practical ways. Clark County (Las Vegas metro) contains roughly 72% of the state's population and has dense pharmacy and telehealth infrastructure. Washoe County (Reno) adds another 15%. The remaining 13% of Nevadans live across 15 largely rural counties where mail-order pharmacy and telehealth are not optional conveniences but primary access routes [16].

The Nevada State Medical Association and the Nevada Telehealth Alliance have both supported expanded telehealth prescribing regulations since the COVID-19 public health emergency formalized audio-video prescribing statewide [17]. Those rules were made permanent under AB 254 (2021 Nevada Legislature), meaning telehealth prescribing of non-controlled substances like dulaglutide is now a stable, codified access pathway rather than an emergency accommodation.

For patients in rural Nevada counties, combining telehealth prescribing with a mail-order pharmacy eliminates the need for any in-person visit. Quest Diagnostics and LabCorp maintain patient service centers in Elko, Fallon, and Carson City, covering the most populated rural Nevada areas for baseline lab draws [4].

Eli Lilly also maintains a patient assistance program called Lilly Cares Foundation, which provides Trulicity at no cost to uninsured or underinsured patients meeting income eligibility criteria (generally at or below 400% of the federal poverty level) [14]. Nevada residents can apply directly through the Lilly Cares website with proof of Nevada residency and income documentation.